ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Market Cap
$58.9M
Volume
19.0K
Cash and Equivalents
$4.6M
EBITDA
$2.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$9.4M
Profit Margin
34.45%
52 Week High
$6.84
52 Week Low
$3.34
Dividend
N/A
Price / Book Value
2.02
Price / Earnings
-203.31
Price / Tangible Book Value
2.03
Enterprise Value
$69.0M
Enterprise Value / EBITDA
20.41
Operating Income
$184.5K
Return on Equity
1.01%
Return on Assets
0.26
Cash and Short Term Investments
$4.6M
Debt
$14.7M
Equity
$29.0M
Revenue
$27.3M
Unlevered FCF
$1.3M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium